However, despite the comprehensive nature of WGS, only a fraction of cases harboured currently targetable genomic alterations, including small numbers of cases with tumour mutation burden (TMB) > 10 per MB and cases with KRAS and PIK3CA mutations. The gene discussed is KRAS; the disease is neoplasm.